Lataa...
Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion
Targeting immune checkpoints, such as PD‐L1 and its receptor PD‐1, has opened a new avenue for treating cancers. Understanding the regulatory mechanism of PD‐L1 and PD‐1 will improve the clinical response rate and efficacy of PD‐1/PD‐L1 blockade in cancer patients and the development of combinatoria...
Tallennettuna:
| Julkaisussa: | EMBO J |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6589543/ https://ncbi.nlm.nih.gov/pubmed/30396996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201899506 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|